ev3 — Foxhollow Technologies — Merger or Acquisition (September 2007)
26 slides from ev3's merger presentation, Sep 10, 2007
Slide 1: September Update 2007
September Update 2007 Jim Corbett CEO
Slide 2: Forward-Looking Statements
This presentation contains "forward-looking statements" about ev3 and FoxHollow within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the benefits of the business combination transaction involving ev3 and FoxHoll
Slide 3: Forward-Looking Statements (continued)
The following factors, among others, could cause actual results to differ materially from the anticipated results or other expectations expressed in the forward-looking statement: general business and economic conditions; the ability to obtain governmental approvals of the transaction on a timely ba
Slide 4: Consistent Revenue Growth
Consistent Revenue Growth Last 5 Quarters Annual Q3 Q4 Q1 Q2 51.9 57.7 61.5 50.6 65.4 1st Qtr 2nd Qtr 3rd Qtr 4th Qtr East 37 68 86 134 202.4 50%+ CAGR $ Millions +29% $37 $68 $86 $134 $202 02 03 04 05 06 $51.9 $57.7 $61.5 $65.4 Q3 Q4 Q1 $ Millions Q2 $50.6 2006 2007
Slide 5: Balanced Revenue Growth
Balanced Revenue Growth Q3 Q3 Q1 Q2 31.1 34.6 35.1 30.7 39.6 +29% $31.1 $34.6 $35.1 Q3 Q4 Q1 Q2 $39.6 $30.7 +30% +24% +33% Total U.S. Total International Worldwide Cardio Peripheral Worldwide Neurovascular Revenues ($ Millions) Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 20.7 23.7 25 20 24.8 Q3 Q4 Q1 Q2 20.8 23.1 26.4
Slide 6: ev3 Growth Drivers
ev3 Growth Drivers 2007 Market ev3 Product Protege ev3 Estimates $150M
Slide 7: Cardio Peripheral
ge ev3 THE ENDOVASCULAR COMPANY Cardio Peripheral
Slide 8: ev3 Carotid Stent and SpiderFX U.S. Launch
Protege Stent Guidewire External Carotid Artery Internal Carotid Artery SpiderFX Filter ev3 Carotid Stent and SpiderFX U.S. Launch Q1 '07
Slide 9: Stents Fracture in Multiple Ways
Stents Fracture in Multiple Ways
Slide 10: Clinical Research in the SFA: A Strategic Commitment
Clinical Research in the SFA: A strategic Commitment- Durability II - SFA FDA Trial 30 sites, 287 patients 30 day MAE, 3 month, 6 month, annually for 5 years Primary endpoints, patency and fracture at 1 year Lesions treated 7-16 CM Durability I- European Efficacy Trial Enrollment Completed 152 patie
Slide 11: Neurovascular
ge ev3 THE ENDOVASCULAR COMPANY Neurovascular
Slide 12: Axium Detachable Coil System
Linear Release System Axium(tm) Detachable Coil System Axium 3D Coil Unique Implant Design Optimized for softness and packability Conformable and stable coil design Platinum and Surface Modified Instant Reliable Detachment Single handed actuator Simple, elegant design WW Detachable Coil Opportunity
Slide 13: Brain AVM
Brain AVM Angio confirms arteriovenous malformation Final angiogram: patient well, no surgery, back to work, no deficit
Slide 14: Hemorrhagic and Ischemic Stroke; SOLO Neurovascular Stent
Hemorrhagic Stroke Aneurysm neck bridging WW Market Opportunity 2005 2010 CAGR $25M $65M 20%+ Ischemic Stroke Stenotic disease Clot retrieval Flow restoration WW Market Opportunity 2005 2010 CAGR $5M $260M 100%+ SOLO(tm) Neurovascular Stent Platform Product Self expanding neurovascular stent Placed
Slide 15: Financial Overview
ge ev3 THE ENDOVASCULAR COMPANY Financial Overview
Slide 16: Improved Operating Performance
Improved Operating Performance 1st Qtr 2nd Qtr 3rd Qtr 4th Qtr East 37 68 86 134 202.4 Increasing Sales Force Productivity EBITDA, Excluding SBC Consistent Revenue Growth Improving Gross Margin Q4 '04 Q4 05 Q4 06 Q1 07 Q2 07 -21.1 -16.5 3 -1.8 -3.5 $(16.5) $3.0 59.5% Q2 05 Q2 06 Q2 07 59.5 64.1 65.8
Slide 17: Creating a Global Leader in Endovascular Devices
CREATING A GLOBAL LEADER IN ENDOVASCULAR DEVICES
Slide 18: Important Additional Information for Investors and Stockholders
Important Additional Information for Investors and Stockholders This communication is being made in respect of the proposed business combination involving ev3 and FoxHollow. In connection with the proposed transaction, ev3 filed with the SEC a registration statement on Form S-4, containing an inform
Slide 19: Participants in the Solicitation
Participants in the Solicitation ev3, FoxHollow and their respective directors and executive officers and other persons may be deemed to be participants in the solicitation of proxies from the stockholders of FoxHollow in respect of the proposed transaction. Information regarding ev3's directors and
Slide 20: Use of Non-GAAP Financial Measures
Use of Non-GAAP Financial Measures In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), ev3 uses the non-GAAP financial measures, such as "adjusted EPS" as supplemental measures of performance and believes these measures facilitate operat
Slide 21: The Union of Need and Solution: The PAD Challenge
The union of need and solution MINIMALLY INVASIVE SOLUTIONS THE PAD CHALLENGE PTA $235 M Atherectomy $200 M Stents $635 M Total Prevalence 8 million people Receive Treatment 2 million No Treatment 6 million Estimated 2007 US Market Size Estimated US Prevalence 1st Qtr 2nd Qtr 3rd Qtr 4th Qtr East 2
Slide 22: Diverse Endovascular Product Offering
Diverse Endovascular Product Offering Best-in-Class Solutions For Peripheral Vascular Disease Stents Everflex Everflex Long Nanoflex* Primus Protege Rx Protege Biggs PTA ..014 ..018 ..035 Longs and large diameters Atherectomy SilverHawk Plaque Excision System TurboHawk RockHawk NightHawk Embolic Pro
Slide 23: Transaction Overview
Transaction Overview Fourth Quarter of 2007 FoxHollow stockholders, customary closing conditions and anti- trust clearance, including HSR Warburg Pincus and The Vertical Group, together owning 56.8% of ev3 shares, have approved ev3's issuance of shares in connection with the transaction and the amen
Slide 24: Guidance
Guidance Revenues: 2008: In the range of $585-$615 million 2009: In the range of $700-$750 million Projected EPS*: 2008: In the range of $0.60 - $0.70 2009: In the range of $0.90 - $1.10 Including the impact of new and existing amortization expense, excluding the impact of one-time costs related to
Slide 25: Creating a Global Leader in Endovascular Devices
CREATING A GLOBAL LEADER IN ENDOVASCULAR DEVICES
Slide 26: The Endovascular Company
ge ev3 THE ENDOVASCULAR COMPANY
Foxhollow Technologies — Merger or Acquisition (September 2007) on 6ix